{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:15Z","timestamp":1761512895424,"version":"3.38.0"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T00:00:00Z","timestamp":1288137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)\u2010interferon (IFN)\u2010\u03b1\u20102a\u2009+\u2009ribavirin (RIBA) may be explained by neutralizing antibodies to IFN\u2010\u03b1\u20102a. The aim of this study was to assess neutralizing antibodies to IFN\u2010\u03b1\u20102a and IFN levels in non\u2010responder patients who were re\u2010treated by PEG IFN\u2010\u03b1\u20102a and RIBA for 12 weeks. Non\u2010responders to a first\u2010line treatment of PEG IFN\u2010\u03b1\u20102a\u2009+\u2009RIBA were included for treatment with PEG IFN\u2010\u03b1\u20102a (180\u2009\u00b5g\/week)\u2009+\u2009RIBA (1,000\u2009mg\/day if &lt;75\u2009kg, 1,200\u2009mg otherwise) for 48 weeks. HCV RNA was measured at week 12. IFN levels and neutralizing antibodies to IFN\u2010\u03b1\u20102a were measured retrospectively on stored sera at baseline and weeks 4 and 12, using a quantitative sandwich ELISA for neutralizing antibodies to IFN\u2010\u03b1\u20102a. Twenty\u2010three patients were non\u2010responders and 19 patients were responders at week 12 of the initial phase of the second\u2010line treatment. Non\u2010responders and responders did not differ statistically: baseline age (median age 47 vs. 50 years), HCV RNA (median 6.8 vs. 6.4 log<jats:sub>10<\/jats:sub>copies\/ml), gender (70% vs. 73% males), genotype (genotype 1: 91% vs. 80%). The median IFN\u2010\u03b1\u20102a levels (pg\/ml) at weeks 0, 4, and 12 (interquartile range) did not differ between the 19 responders to initial phase of second\u2010line treatment and the 23 non\u2010responders: &lt;3.3 (&lt;3.3\u2013371.4), 1457.3 (106.8\u20133284.8), and 1,652 (90.8\u20135,000); 84.5 (3.3\u2013277.4), 1407.4 (120.2\u20132443.4), and 1620.1 (120.2\u20132287.1), respectively. Among non\u2010selected consecutive non\u2010responder patients, re\u2010treatment with PEG IFN\u2010\u03b1\u20102a\u2009+ RIBA is associated with virological response regardless of the presence of antibody\u2010mediated resistance to conventional IFN treatment. J. Med. Virol. 82:2027\u20132031, 2010. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jmv.21909","type":"journal-article","created":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T18:20:53Z","timestamp":1288203653000},"page":"2027-2031","source":"Crossref","is-referenced-by-count":8,"title":["Neutralizing antibodies to interferon\u2010\u03b1 and circulating interferon in patients with chronic hepatitis C non\u2010responding to pegylated interferon plus ribavirin re\u2010treated by pegylated interferon\u2010\u03b1\u20102a and ribavirin (ANRS HC16 GAMMATRI substudy*)"],"prefix":"10.1002","volume":"82","author":[{"given":"Philippe","family":"Halfon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"P\u00e9rusat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Trimoulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Foucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Penaranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Couzigou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ANRS HC16 GAMMATRI Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.4.882"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.43747.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.08.007"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03579.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.021"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08309"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360704"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20506"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80309-7"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.009"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00651.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1993.tb00622.x"},{"key":"e_1_2_7_14_1","first-page":"201","article-title":"Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN","volume":"42","author":"Milella M","year":"1995","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.039"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210307"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff LB","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.083113"},{"key":"e_1_2_7_20_1","first-page":"S22","article-title":"Management of patients with chronic hepatitis C virus infection and previous nonresponse","volume":"4","author":"Shiffman ML","year":"2004","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2005.05.003"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08463"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052880"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-3-24"},{"key":"e_1_2_7_27_1","unstructured":"WHO.2000.Hepatitis C Fact Sheet No. 164."}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.21909","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.21909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T09:49:18Z","timestamp":1740649758000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.21909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,27]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1002\/jmv.21909"],"URL":"https:\/\/doi.org\/10.1002\/jmv.21909","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"type":"print","value":"0146-6615"},{"type":"electronic","value":"1096-9071"}],"subject":[],"published":{"date-parts":[[2010,10,27]]}}}